FDA Approves Groundbreaking Drug to Slow Alzheimer's Disease

The FDA has granted approval to Leqembi, a drug developed by Japanese drugmaker Eisai and US-based Biogen, making it the first approved treatment that can slow the progression of Alzheimer's. Leqembi works by reducing amyloid plaques in the brain, addressing the underlying biology of the disease. However, it is not a cure and requires professional administration every two weeks. The drug's high cost of $26,500 per year may limit accessibility, with Medicare unlikely to cover it. The number of Americans with Alzheimer's is expected to increase, leading to a greater focus on treatments and diagnostics for the disease.